Pembrolizumab as a first-line treatment was also effective in drastic tumor growth suppression with just a single dose, giving rise to an asymptomatic and clinical partial response with no adverse effects in a 69-year-old female with mediastinal SMARCA4-DTS with metastasis and a positive tumor cell PD-L1 status of > 60% [41]. The gene discussed is CD274; the disease is neoplasm.